Skip to content

A systematic study on the syndrome differentiation standard of lingnan wet syndrome - ulcerative colitis

A systematic study on the syndrome differentiation standard of lingnan wet syndrome - ulcerative colitis

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006063
Enrollment
Unknown
Registered
2022-06-05
Start date
2022-06-05
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

Pure western medicine intervention:Mesalazine
Intervention of integrated Chinese and Western medicine:Mesalazine + invigorating spleen and removing dampness
Simple Chinese medicine intervention:Shenling Baizhu powder + special prescription

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria of UC in Western medicine; (2) Aged between 18 and 75; (3) Signed informed consent with good compliance and can be followed up; (4) Normal cognitive function, no dyslexia, can actively cooperate with the investigation and research.

Exclusion criteria

Exclusion criteria: (1) Chronic schistosomiasis, bacterial dysentery, intestinal tuberculosis and other infectious colitis, colonic Crohn's disease, radiation enteritis, ischemic enteritis; (2) Patients in lactation, pregnant women and intolerant to this drug; (3) patients with serious primary diseases such as heart, lung, liver, kidney and hematopoietic system, and mental illness; (4) Patients with serious complications such as local stenosis, toxic megacolon, intestinal obstruction, colon cancer, rectal cancer, intestinal perforation and anal diseases; (5) persons with disabilities defined by law (mute, deaf, blind, mental disorder, physical disability, intellectual disability).

Design outcomes

Primary

MeasureTime frame
Disease recurrence rate;

Secondary

MeasureTime frame
erythrocyte sedimentation rate;Inflammatory Bowel Disease Quality of Life Questionnaire;TCM wet syndrome evaluation scale;c reactive protein;UC Disease activity index;Individual symptom efficacy;TCM syndrome effect;

Countries

China

Contacts

Public Contacthuangshaogang
huangshaogang@gzucm.edu.cn13926451320

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026